GET DAILY SIGNALSLiquidia Corporation (LQDA) Analyst Target at $53: Is +11% Upside Within Reach?
Key Takeaways
- The central price target of $53 is the arithmetic mean of eight current analyst price targets, not an official published consensus.
- Individual targets range widely, from $33 (Wells Fargo) to $70 (BTIG), reflecting deep disagreement after a legal settlement narrowed the company's growth story.
- With shares recently trading near $47.87, reaching $53 would require a rise of roughly 11% — a modest move by historical standards for this volatile stock.
- The strongest supports are YUTREPIA's commercial traction and the removal of patent-litigation overhang; the biggest risks are a narrowed label and a depleted cash position.
- For more detail on Major News, Today's Price Move, the Forecast, and Earnings, explore Tickeron's dedicated LQDA pages.
- Readers can also discover data-driven ideas by exploring Trending AI Robots.
What Analysts Are Projecting for LQDA
Liquidia Corporation (LQDA), a Morrisville, North Carolina–based biopharmaceutical company focused on rare cardiopulmonary diseases, is covered by eight analysts with current price targets. Calculating the arithmetic mean of those eight targets yields roughly $53.13, rounded to a central target of $53 for this analysis.
The spread is unusually wide — from $33 at Wells Fargo (Hold/Equal Weight) to $70 at BTIG (Buy). The range reflects how divided Wall Street remains after a settlement with United Therapeutics. Post-settlement revisions were dramatic: H.C. Wainwright raised its target from $58 to $65 (Buy), BTIG set $70 while upgrading its rating, Wells Fargo edged up to $33, Bank of America Securities moved to $42 (Hold), and Needham trimmed to $58. Raymond James cut its target to $53 while downgrading the stock to Outperform, and Jefferies maintained $45 (Buy). Six of eight ratings are Buy or Strong Buy; two are Hold, with no Sell ratings currently published.
Where LQDA Stands Today and the Path to $53
Shares recently closed near $47.87, meaning a move to $53 represents about an 11% gain — a modest step for a stock that has swung between roughly $22 and $94 over the past year. The path is plausible but not assured. YUTREPIA (treprostinil) inhalation powder, approved for pulmonary arterial hypertension (PAH), has delivered consecutive profitable quarters and captured a meaningful share of the inhaled treprostinil market. However, the October litigation settlement reportedly narrowed YUTREPIA's label to PAH, reducing the addressable opportunity and explaining why most targets sit far below the triple-digit levels seen earlier in 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support a Move Higher
Commercial execution is the central pillar. Liquidia reported first-quarter 2026 revenue near $130 million with EPS (earnings per share) of $0.52, beating consensus and marking a third straight profitable quarter. Removing the United Therapeutics litigation overhang eliminates a major legal discount that had pressured the valuation. Continued prescription growth, prescriber adoption, and progress on L606 — the investigational extended-release treprostinil candidate — could support analyst estimates and sentiment.
Risks That Could Keep the Target Out of Reach
The settlement's terms are the key risk. A narrowed label and a substantially reduced cash position limit both near-term revenue upside and strategic flexibility. The company's valuation still embeds expectations for growth that may be harder to achieve with a smaller indication base. Wells Fargo's $33 target, below the current price, underscores the bearish case: that even with litigation resolved, the revised revenue trajectory may not justify the current multiple. Competition in pulmonary hypertension and any setbacks in the L606 program or label-expansion efforts would add further pressure.
Technical Levels Worth Watching
The stock's 52-week range of roughly $22 to $94 illustrates extreme volatility. An early-October patent decision triggered a sharp decline of roughly 48%, followed by a partial recovery after the settlement was announced. The $50 level is a nearby psychological round number, with the $53 target sitting just above it. On the downside, the mid-$40s and the low-$40s zone represent areas of recent trading support, while prior highs in the $60–$70 range mark resistance well above the current target.
What to Monitor Going Forward
Analyst price targets generally reflect a roughly 12-month horizon, though individual firms may differ. Investors should watch quarterly YUTREPIA prescription and revenue trends, any updates on label expansion, L606 clinical milestones, and whether analysts revise targets as the post-settlement financial picture becomes clearer. Cash runway commentary on earnings calls will be particularly important given the settlement's cash impact, as will any further litigation or competitive developments in PAH and PH-ILD (pulmonary hypertension associated with interstitial lung disease).
Using Tickeron’s AI Daily Buy/Sell Signals in My Process
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing research, the tool helps traders discover opportunities, monitor positions, and spot shifting trends more efficiently. For investors tracking a fast-moving, event-driven name like LQDA, automated signal monitoring can complement fundamental analysis by flagging momentum changes in near real time.
Final Assessment
Can Liquidia Corporation (LQDA) stock reach $53? The question is not unreasonable: the $53 central target, derived from eight analyst price targets, sits only about 11% above the latest close and is backed by real commercial progress in YUTREPIA and the removal of litigation overhang. Yet the extraordinarily wide $33-to-$70 range shows analysts remain divided on whether the narrowed label and reduced cash balance justify the valuation. Reaching $53 is a modest hurdle, but the trajectory will depend on sustained YUTREPIA growth, L606 execution, and disciplined cash management. No outcome is guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LQDA's RSI Oscillator climbs out of oversold territory
The RSI Indicator for LQDA moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LQDA as a result. In 70 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for LQDA just turned positive on October 16, 2026. Looking at past instances where LQDA's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.
LQDA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +15.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in 280 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 200 of 247 cases where LQDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 68 cases where LQDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
The 50-day moving average for LQDA moved below the 200-day moving average on October 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
LQDA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LQDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.369) is normal, around the industry mean (6.379). P/E Ratio (28.101) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (14.286) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of particle-based vaccines and therapeutics for prevention and treatment of human disease
Industry PharmaceuticalsGeneric
Advertisement